{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:45:01Z","timestamp":1790729101047,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>The advent of immune checkpoint inhibitors (ICIs), although associated with adverse events, has heralded a new era in cancer therapy. ICI-related pancreatitis is a rare adverse effect of ICIs. The nonspecific clinical manifestations have posed diagnostic challenges, and the detailed histologic features remain largely unknown. This study aims to characterize the clinical and histopathologic features of ICI-related pancreatitis to increase awareness and improve diagnostic accuracy. We retrospectively identified 5 specimens from 4 patients from our database and consultation practice. We reviewed demographic, clinical, serological, and radiologic data and examined each specimen\u2019s histologic features. Patients (2 female, 2 male) were all prescribed anti-PD-1 monoclonal antibodies (1 on Nivolumab and 3 on Pembrolizumab) for metastatic melanoma, unresectable colon cancer, metastatic pancreatic adenocarcinoma, and urothelial carcinoma. The onset of ICI-related pancreatitis ranged from 28 to 473 days after ICI initiation.\u202fAll 4 patients showed elevated amylase and\/or lipase. Two patients presented with the chief complaint of abdominal pain. The other 2 initially asymptomatic patients showed hypointense mass lesions on imaging resembling malignant processes. The most common histologic findings were acinar-centric mixed inflammatory infiltrate (5\/5 specimens) followed by atrophy (4\/5 specimens) and fibrosis (4\/5 specimens). Storiform fibrosis was identified in one patient who was biopsied twice. Other findings included edema (3\/5 specimens) and acinar-to-ductal metaplasia (3\/5 specimens). Granulocytic epithelial lesion was identified in 2 specimens. No obliterative phlebitis or granulomas were identified. By immunohistochemistry, the inflammatory infiltrates were predominately composed of CD3+ T cells with a variable CD4 to CD8 ratio. Neutrophils and eosinophils were readily identifiable with rare plasma cells. Management\u202fincluded stopping the ICI and starting steroids. Whereas 1 patient lacked follow-up information, 2 patients showed marked improvement. One patient succumbed to severe ICI-related myocarditis.\u202fIn conclusion, ICI-related pancreatitis shows overlapping clinical-radiologic features with malignancy and autoimmune pancreatitis with the potential for chronic injury. Although ICI-related pancreatitis lacks the classic histologic features of autoimmune pancreatitis, there is considerable histologic overlap, particularly on small biopsies. Therefore, correlation with the patient\u2019s medications is critical when evaluating pancreatic specimens with nonspecific chronic pancreatitis histologic patterns.<\/jats:p>","DOI":"10.1097\/pas.0000000000002398","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:10:24Z","timestamp":1744024224000},"page":"730-739","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Clinicopathologic Characteristics of Immune Checkpoint Inhibitor-related Pancreatitis"],"prefix":"10.1097","volume":"49","author":[{"given":"Feidi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Vyas","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gosse","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa Hospitals & Clinics, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"R1-20250618","doi-asserted-by":"crossref","first-page":"627612","DOI":"10.3389\/fonc.2021.627612","article-title":"Immunotherapy-associated pancreatic adverse events: current understanding of their mechanism, diagnosis, and management","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"R2-20250618","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/healthcare10050763","article-title":"Clinical characteristics of ICI-related pancreatitis and cholangitis including radiographic and endoscopic findings","volume":"10","author":"Nakano","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"R3-20250618","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAS.0000000000001730","article-title":"Histopathology of gastrointestinal immune-related adverse events: a practical review for the practicing pathologist","volume":"46","author":"Zhang","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R4-20250618","first-page":"516","article-title":"Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis)","volume":"38","author":"Sayed Ahmed","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"key":"R5-20250618","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R6-20250618","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"R7-20250618","first-page":"49","article-title":"Management of acute pancreatitis associated with checkpoint inhibitors","volume":"11","author":"Rogers","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"R8-20250618","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2018.0047","article-title":"New NCCN Guidelines: Recognition and management of immunotherapy-related toxicity","volume":"16","author":"Thompson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"R9-20250618","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"key":"R10-20250618","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11523-019-00694-w","article-title":"Immune checkpoint inhibitor-induced pancreatic injury: imaging findings and literature review","volume":"15","author":"Porcu","year":"2020","journal-title":"Target Oncol"},{"key":"R11-20250618","doi-asserted-by":"crossref","first-page":"109250","DOI":"10.1016\/j.ejrad.2020.109250","article-title":"Imaging findings of immune checkpoint inhibitor associated pancreatitis","volume":"131","author":"Das","year":"2020","journal-title":"Eur J Radiol"},{"key":"R12-20250618","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejca.2017.05.042","article-title":"Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas","volume":"82","author":"Rawson","year":"2017","journal-title":"Eur J Cancer"},{"key":"R13-20250618","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2018.02.006","article-title":"Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?","volume":"95","author":"Capurso","year":"2018","journal-title":"Eur J Cancer"},{"key":"R14-20250618","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.2337\/dc18-2518","article-title":"T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"R15-20250618","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pan.2020.11.002","article-title":"An autopsy case of severe acute pancreatitis induced by administration of pazopanib following nivolumab","volume":"21","author":"Tanaka","year":"2021","journal-title":"Pancreatology"},{"key":"R16-20250618","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1097\/MPA.0000000000001756","article-title":"Pancreatic atrophy in nivolumab-associated pancreatitis mimics autoimmune pancreatitis","volume":"50","author":"Janssens","year":"2021","journal-title":"Pancreas"},{"key":"R17-20250618","doi-asserted-by":"crossref","first-page":"e243360","DOI":"10.1136\/bcr-2021-243360","article-title":"Simultaneous occurrence of autoimmune pancreatitis and sclerosing cholangitis as immune-related adverse events of pembrolizumab","volume":"14","author":"Suda","year":"2021","journal-title":"BMJ Case Rep"},{"key":"R18-20250618","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s12328-021-01499-z","article-title":"Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer","volume":"14","author":"Ofuji","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"R19-20250618","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1016\/j.cgh.2021.10.015","article-title":"Rare case of nivolumab-induced chronic pancreatitis","volume":"20","author":"Song","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R20-20250618","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2169\/internalmedicine.8507-21","article-title":"Pembrolizumab-induced focal pancreatitis diagnosed by endoscopic ultrasound-guided fine-needle aspiration","volume":"61","author":"Ikemoto","year":"2022","journal-title":"Intern Med"},{"key":"R21-20250618","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.2169\/internalmedicine.9565-22","article-title":"Neutrophil infiltration and acinar-ductal metaplasia are the main pathological findings in pembrolizumab-induced pancreatitis","volume":"61","author":"Hirota","year":"2022","journal-title":"Intern Med"},{"key":"R22-20250618","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pathol.2022.04.010","article-title":"IgG4-related autoimmune pancreatitis-like mass-forming lesion on a background of immune checkpoint inhibitor immunotherapy","volume":"55","author":"Champion","year":"2023","journal-title":"Pathology"},{"key":"R23-20250618","doi-asserted-by":"crossref","first-page":"933595","DOI":"10.3389\/fimmu.2022.933595","article-title":"The diagnosis of immune-related pancreatitis disguised as multifocal lesions on MRI by endoscopic ultrasound-guided fine-needle biopsy: a case report","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"R24-20250618","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2337\/db22-0557","article-title":"Inflammatory cell infiltration into islets without PD-L1 expression is associated with the development of immune checkpoint inhibitor-related type 1 diabetes in genetically susceptible patients","volume":"72","author":"Kawata","year":"2023","journal-title":"Diabetes"},{"key":"R25-20250618","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2169\/internalmedicine.1943-23","article-title":"Immune checkpoint inhibitor-induced pancreatitis with pancreatic enlargement mimicking autoimmune pancreatitis: a case report and review of the literature","volume":"63","author":"Tanabe","year":"2024","journal-title":"Intern Med"},{"key":"R26-20250618","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R27-20250618","doi-asserted-by":"crossref","first-page":"109275","DOI":"10.1016\/j.ejrad.2020.109275","article-title":"Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors","volume":"132","author":"Park","year":"2020","journal-title":"Eur J Radiol"},{"key":"R28-20250618","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","article-title":"Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center","volume":"73","author":"El Majzoub","year":"2019","journal-title":"Ann Emerg Med"},{"key":"R29-20250618","doi-asserted-by":"crossref","first-page":"djw260","DOI":"10.1093\/jnci\/djw260","article-title":"Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with Nivolumab + Ipilimumab","volume":"109","author":"Friedman","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"R30-20250618","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/jgh3.12875","article-title":"Pancreatic adverse events in patients treated with immune checkpoint inhibitors","volume":"7","author":"Hana","year":"2023","journal-title":"JGH Open"},{"key":"R31-20250618","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.gastro.2022.09.042","article-title":"Autoimmune pancreatitis secondary to immune checkpoint inhibitor therapy (Type 3 AIP): insights into a new disease from serial pancreatic imaging","volume":"164","author":"Thomas","year":"2023","journal-title":"Gastroenterology"},{"key":"R32-20250618","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1158\/2326-6066.CIR-17-0659","article-title":"Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study","volume":"6","author":"Eshet","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"R33-20250618","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"R34-20250618","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5858\/arpa.2021-0549-RA","article-title":"Navigating the challenges associated with a diagnosis of autoimmune pancreatitis and igg4-related sclerosing cholangitis","volume":"147","author":"Yilmaz","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"R35-20250618","first-page":"00002","article-title":"Autoimmune pancreatitis: biopsy interpretation and differential diagnosis","volume":"S0740-2570","author":"Zen","year":"2024","journal-title":"Semin Diagn Pathol"},{"key":"R36-20250618","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/his.14197","article-title":"Prevalence of histological features resembling autoimmune pancreatitis in neoplastic pancreas resections","volume":"77","author":"Chen","year":"2020","journal-title":"Histopathology"},{"key":"R37-20250618","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3390\/ijerph6112763","article-title":"Alcoholic pancreatitis: pathogenesis, incidence and treatment with special reference to the associated pain","volume":"6","author":"Pezzilli","year":"2009","journal-title":"Int J Environ Res Public Health"},{"key":"R38-20250618","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R39-20250618","doi-asserted-by":"crossref","first-page":"1205720","DOI":"10.3389\/fonc.2023.1205720","article-title":"Rituximab in steroid-refractory immune-related pancreatitis: a case report","volume":"13","author":"Santoro","year":"2023","journal-title":"Front Oncol"},{"key":"R40-20250618","doi-asserted-by":"crossref","first-page":"928390","DOI":"10.3389\/fonc.2022.928390","article-title":"The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy","volume":"12","author":"Bruera","year":"2022","journal-title":"Front Oncol"},{"key":"R41-20250618","doi-asserted-by":"crossref","first-page":"e156330","DOI":"10.1172\/jci.insight.156330","article-title":"Immune cells and their inflammatory mediators modify \u03b2 cells and cause checkpoint inhibitor-induced diabetes","volume":"7","author":"Perdigoto","year":"2022","journal-title":"JCI Insight"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T21:00:18Z","timestamp":1750280418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002398","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}